JCR Pharmaceuticals : Notice Regarding Change of Directors and Nomination of Candidates for New Members of the Board of Directors

News Release

April 27, 2021

JCR Pharmaceuticals Co., Ltd.

Translation

Notice Regarding Change of Directors and Nomination of Candidates for New

Members of the Board of Directors

Apr. 27, 2021 -- JCR Pharmaceuticals Co., Ltd. (TSE 4552; Chairman and President: Shin Ashida; "JCR") announced that its Board of Directors resolved at a meeting held today to submit a proposal regarding the change of Directors and nomination of candidates for the Board of Directors to be presented before JCR's Ordinary General Meeting of Shareholders scheduled in June, 2021.

The change of Directors and appointment of the new Members of the Board will be subject to approval at the Ordinary General Meeting of Shareholders.

1. Promoting Director
Senior Vice President	Toru Ashida (Current Vice President)
Vice President	Mathias Schmidt, PD, Ph,D. (Current Senior Executive Director)
Vice President	Hiroyuki Sonoda, Ph.D. (Current Senior Executive Director)

2. Assignment of Responsibility to Director

Name	New Areas of responsibility/	Current Areas of responsibility/
Concurrent position	Concurrent position
	Sales and Administration		Corporate Strategy and Sales
Toru Ashida		Division
Executive Director, Sales Division
	Executive Director, Sales Division
	Clinical	Development,	Global
Mathias	Business	Strategy and	Business	Global Strategy
Schmidt, PD,	Development		ArmaGen, Inc. CEO
Ph,D.	ArmaGen, Inc. CEO		JCR USA, Inc. President and CEO
	JCR USA, Inc. President and CEO
Hiroyuki				Research and Development Division
Research and Corporate Strategy	Executive Director, Research Division
Sonoda,
Executive Director, Research Division	Director, Drug Discovery Research,
Ph.D.
			Research Division

3. Candidates for New Directors

Name	Yoshio Hiyama, Ph.D.
Career	Apr. 1998 Entered Daiichi Pharmaceuticals Co., Ltd. (currently Daiichi
	Sankyo Co., Ltd.)

Oct. 1999 PMD-VAC Co., Ltd (secondment), Manager, Regulatory Affairs Group

Apr. 2005 (ditto) Marketing Supervisor General and General Manager Oct. 2011 Daiichi Sankyo Co., Ltd (returned), Group Manager,

R&D Group in Vaccine Planning Dept.

Jul. 2012 Japan Vaccines Co. Ltd. (secondment), Marketing Supervisor General and Quality and Safety management director

Mar. 2019 Dissolution of Japan Vaccines Co, Ltd.

Apr. 2019 Entered JCR Pharmaceuticals Co., Ltd. Assistant director, Production Division

Apr. 2020 Marketing Supervisor General (current post), Pharmacovigilance Dept. director and PMS office manager

Sep. 2020 Corporate Planning Division director (Vaccine Business), and Pharmacovigilance Dept. assistant director (current post)

4. Retiring Director

Hiroshi Yoshimoto (current position: Representative Director, Senior Vice President, Head of Production Division and Executive Director, Production Division)

Mr. Yoshimoto will be appointed "Senior Advisor" at a Board Meeting as scheduled on June, 2021.

Members of the Board of Internal Directors (Planned after a Board Meeting on June, 2021)

Title		Name	Areas of responsibility/
			Concurrent position
Representative	Director	Shin Ashida	-
and Chairman,	President
& CEO
Senior Vice President	Toru Ashida	Sales and Administration
			Executive Director, Sales Division
Vice President		Mathias Schmidt,	Clinical Development, Global Business
		PD, Ph.D.	Strategy and Business Development
			ArmaGen, Inc. CEO
			JCR USA, Inc. President and CEO
Vice President		Hiroyuki Sonoda,	Research and Corporate Strategy
		Ph.D.	Executive Director, Research Division
Senior Executive Director	Yoshio Hiyama,	Production and Quality Assurance
		Ph.D.	Executive Director, Production Division

About JCR Pharmaceuticals Co., Ltd.

JCR Pharmaceuticals Co., Ltd. (TSE 4552) is a global specialty pharmaceuticals company that is redefining expectations and expanding possibilities for people with rare and genetic diseases worldwide. We continue to build upon our 45-year legacy in Japan while expanding our global footprint into the US, Europe, and Latin America. We improve patients' lives by applying our scientific expertise and unique technologies to research, develop, and deliver next-generation therapies. Our approved products in Japan include therapies for the treatment of growth disorder, Fabry disease, acute graft-versus host disease, and renal anemia. Our investigational products in development worldwide are aimed at treating rare diseases including MPS I (Hurler, Hurler- Scheie and Scheie syndrome), MPS II (Hunter syndrome), Pompe disease, and more. JCR strives

to expand the possibilities for patients while accelerating medical advancement at a global level. Our core values - reliability, confidence, and persistence - benefit all our stakeholders, including employees, partners, and patients. Together we soar. For more information, please visit https://www.jcrpharm.co.jp/en/site/en/.

Cautionary Statement Regarding Forward-Looking Statements

This document contains forward-looking statements that are subject to known and unknown risks and uncertainties, many of which are outside our control. Forward-looking statements often contain words such as "believe," "estimate," "anticipate," "intend," "plan," "will," "would," "target" and similar references to future periods. All forward-looking statements regarding our plans, outlook, strategy and future business, financial performance and financial condition are based on judgments derived from the information available to us at this time. Factors or events that could cause our actual results to be materially different from those expressed in our forward-looking statements include, but are not limited to, a deterioration of economic conditions, a change in the legal or governmental system, a delay in launching a new product, impact on competitors' pricing and product strategies, a decline in marketing capabilities relating to our products, manufacturing difficulties or delays, an infringement of our intellectual property rights, an adverse court decision in a significant lawsuit and regulatory actions.

This document involves information on pharmaceutical products (including those under development). However, it is not intended for advertising or providing medical advice. Furthermore, it is intended to provide information on our company and businesses and not to solicit investment in securities we issue.

Except as required by law, we assume no obligation to update these forward-looking statements publicly or to update the factors that could cause actual results to differ materially, even if new information becomes available in the future.

Contact:

Investors & Media:

JCR Pharmaceuticals Co., Ltd. Corporate Communications [e-mail]

###